On the contrary, tumor cell apoptosis rates were modestly but significantly increased in both subcutaneous and pleural tumors from bortezomib-treated mice, a finding consistent with the aforementioned NF-κB inhibitory effects of the employed bortezomib regimen. This evidence concerns the gene NFKB1 and pleural neoplasm.